Published in Curr Drug Targets on December 01, 2006
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet (2009) 0.95
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol (2011) 0.87
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One (2015) 0.82
Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics (2015) 0.79
Pharmacogenetics in Ghana: reviewing the evidence. Ghana Med J (2011) 0.79
Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. Pharmacogenomics (2015) 0.78
VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients. J Stroke (2013) 0.77
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med (2010) 0.77
Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis. PLoS One (2015) 0.77
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci (2011) 0.76
Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metabol Personal Ther (2017) 0.75
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. Int J Clin Exp Pathol (2015) 0.75
Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences. Pharmacogenomics J (2016) 0.75
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
COPD prevalence in a random population survey: a matter of definition. Eur Respir J (2007) 2.97
Risk of venous thromboembolism in users of hormone replacement therapy. Lancet (1996) 2.92
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90
IMGT, the international ImMunoGeneTics database. Nucleic Acids Res (1997) 2.43
Antagonist discrimination between ganglionic and ileal muscarinic receptors. Br J Pharmacol (1980) 2.31
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 2.02
Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J (2009) 1.99
The stereochemistry of the hydrogen elimination in the biological conversion of cholest-7-en-3-beta-ol into cholesterol. Biochem J (1967) 1.98
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Axonal GABA-receptors in mammalian peripheral nerve trunks. Brain Res (1978) 1.97
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther (2013) 1.94
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol (2013) 1.77
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis (2003) 1.59
Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg (2003) 1.59
Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2000) 1.57
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer (2002) 1.49
Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med (1999) 1.48
Laser capture microscopy. Mol Pathol (2000) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Reduction of polypharmacy by feedback to clinicians. J Gen Intern Med (1991) 1.41
Measles immunisation. Aust J Public Health (1992) 1.38
Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy. Vet Rec (2003) 1.37
A very simple method for recording ganglion depolarization. J Physiol (1975) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics (1999) 1.34
Current concepts in the development of heterotopic ossification. J Bone Joint Surg Br (2004) 1.32
Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics (1998) 1.30
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 1.29
Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer (2001) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J (2004) 1.27
Indirect effects of amino-acids on sympathetic ganglion cells mediated through the release of gamma-aminobutyric acid from glial cells. Br J Pharmacol (1976) 1.25
Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer (1999) 1.24
Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics (2000) 1.24
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther (2001) 1.24
Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med (2000) 1.23
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet (1999) 1.19
Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol (1996) 1.18
Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res (2001) 1.18
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther (2007) 1.16
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep (2007) 1.11
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer (2001) 1.09
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol (2001) 1.09
Lessons learned from the irinotecan metabolic pathway. Curr Med Chem (2003) 1.08
Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol (2001) 1.08
Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer (2000) 1.08
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer (2000) 1.08
Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol (2001) 1.07
Physical linkage of the fragile site FRA11B and a Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Mol Genet (1994) 1.07
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res (1998) 1.06
Population variation in VKORC1 haplotype structure. J Thromb Haemost (2006) 1.05
Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer (2001) 1.05
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res (2001) 1.04
Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer (2001) 1.04
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J (2007) 1.03
Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat (2000) 1.03
Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep (2001) 1.03
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer (1998) 1.02
Cancer pharmacogenetics. Br J Cancer (2004) 1.01
Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res (1999) 1.01
Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res (2000) 0.99
c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer (2002) 0.99
Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics (2001) 0.99
Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther (2000) 0.98
Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest (1993) 0.98
Angiotensin mimics the action of muscarinic agonists on rat sympathetic neurones. Brain Res (1980) 0.97
Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J (2010) 0.97
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer (2005) 0.96
Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. Intern Med J (2010) 0.95
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer (2011) 0.94
The glycerol kinase gene family: structure of the Xp gene, and related intronless retroposons. Hum Mol Genet (1994) 0.94
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther (2007) 0.94
An integrated YAC map of the human X chromosome. Genome Res (1996) 0.93
Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet (2000) 0.92
Smoking and COPD: What really are the risks? Eur Respir J (2006) 0.91
Crohn's disease: ethnic variation in CARD15 genotypes. Gut (2003) 0.91
Experimental classical bovine spongiform encephalopathy: definition and progression of neural PrP immunolabeling in relation to diagnosis and disease controls. Vet Pathol (2010) 0.90
The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther (2009) 0.90
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol (1998) 0.90
Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res (1999) 0.90
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer (2003) 0.89
Distribution of gaba-receptors and gaba-carriers in the mammalian nervous system. J Physiol (Paris) (1979) 0.89